Anthony Ekwenchi, MD
Hospice and Palliative Medicine · Austell, GANPI 1376765180
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 310 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,442, 9.1 times the $158 reported in 2019. Among hospice and palliative medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$704
- Teva Pharmaceuticals USA, Inc.$583
- Otsuka America Pharmaceutical, Inc.$387
- Alkermes, Inc.$342
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,21199%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,084 |
| Supernus Pharmaceuticals, Inc. | 40 | $704 |
| Teva Pharmaceuticals USA, Inc. | 36 | $583 |
| Otsuka America Pharmaceutical, Inc. | 23 | $387 |
| Alkermes, Inc. | 19 | $342 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $340 |
| Neurocrine Biosciences, Inc. | 19 | $338 |
| Johnson & Johnson | 17 | $297 |
| Vanda Pharmaceuticals Inc. | 16 | $257 |
| Sunovion Pharmaceuticals Inc. | 10 | $235 |
| Eisai Inc. | 4 | $76 |
| Avion Pharmaceuticals | 4 | $75 |
| Lundbeck LLC | 4 | $72 |
| Idorsia Pharmaceuticals US Inc | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Corium, LLC | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Ironshore Pharmaceuticals Inc. | 3 | $46 |
| Noven Therapeutics, LLC | 2 | $34 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
| Masimo Corporation | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Neuronetics, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$5,262 in reported general payments places this provider in the 95th percentile of 69 hospice and palliative medicine providers in Georgia.
See all hospice and palliative medicine providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 55 | $196,032 |
| VraylarCariprazine Hcl | 52 | $81,270 |
| FanaptIloperidone | 13 | $18,492 |
| RexultiBrexpiprazole | 11 | $16,234 |
| Quetiapine Fumarate | 612 | $14,031 |
| Chlorpromazine Hcl | 83 | $13,615 |
| Lurasidone Hcl | 20 | $12,041 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $10,440 |
| Divalproex Sodium ErDivalproex Sodium | 179 | $8,600 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $7,042 |
| Ziprasidone Hcl | 102 | $6,842 |
| Oxcarbazepine | 134 | $5,776 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,000 |
| Risperidone | 591 | $4,962 |
| Clozapine | 66 | $4,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $297 | $196,03255 claims |
| AbbVieVraylar | $1,084 | $81,27052 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $257 | $18,49213 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $387 | $16,23411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $66 | $5,00011 claims |
| Eisai Inc.Dayvigo | $76 | $4,32413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hospice and palliative medicine providers in Georgia.
Other hospice and palliative medicine in Austell
- Anjali GrandhigeAustell$315
- Gary DerussoAustell$159
- Pamela GordonAustell$128
- Kristian StodghillAustell$110
- Veronica SudekumWarner Robins$7K
- Joshua JacksonAtlanta$5K
- Nokuthula MsimangaMarietta$3K
- Halima DaboikoKennesaw$3K
- Michelle ParkMarietta$2K
- Olumuyiwa AdeboyeLagrange$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.